SCHEMBL6921117

SCHEMBL6921117

CC1(C)CC(F)c2nc3cc(-c4ccccn4)ccc3c(=O)n2C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
METAP2 P50579 2/20 0.37
TNKS O95271 3/20 0.37
PIK3CA P42336 5/20 0.36
PIK3CD O00329 4/20 0.36
PIK3CG P48736 4/20 0.36
PIK3CB P42338 3/20 0.36
TGFBR1 P36897 1/20 0.35
CTSD P07339 1/20 0.35
BACE1 P56817 1/20 0.35
DHODH Q02127 1/20 0.35
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
GSK3B P49841 1/20 0.34
DYRK1A Q13627 1/20 0.34
NPY5R Q15761 1/20 0.34
ALDH1A1 P00352 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14238852 0.88 TNKS (0.39) METAP2TNKSPIK3CAPIK3CDPIK3CG
SCHEMBL14238866 0.86 METAP2 (0.39) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL6922353 0.81 POLB (0.42) ABL1
SCHEMBL12059073 0.80 NPC1 (0.40) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL6921660 0.79 CYP3A4 (0.38) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL6921116 0.79 CACNA2D1 (0.37) BCHEACHEALDH1A1
SCHEMBL6922413 0.78 NPC1 (0.43) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL6922591 0.78 CYP3A4 (0.41) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL6920771 0.78 KDM4E (0.39) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL14239134 0.78 KMT2A (0.39) CYP3A4METAP2TNKSPIK3CAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012170845-A2 METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF HEFFERNAN MICHELE L R (US) 2012-12-13 WO disclosed
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885METAP2 2203/4885TNKS 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.